CO-TRANSPLANTATION OF MESENCHYMAL STEM CELLS CAN AMELIORATES ACUTE GVHD AND VIREMIA AFTER ALLO-HSCT FOR APLASTIC ANEMIA: A MULTI-CENTER RETROSPECTIVE STUDY OF 75PATIENTS
Author(s): ,
Minmin Chen
Affiliations:
hemotology,Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital,Fuzhou,China
,
Zhihong Zheng
Affiliations:
hemotology,Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital,Fuzhou,China
,
Jianda Hu
Affiliations:
hemotology,Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital,Fuzhou,China
Ting Yang
Affiliations:
hemotology,Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital,Fuzhou,China
EHA Library. Chen z. Jun 15, 2019; 267154; PS1537
zhen Chen
zhen Chen
Contributions
Abstract

Abstract: PS1537

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
Mesenchymal stem cells (MSCs) are known to exhibit immunomodulatory, anti-inflammatory, and pro-angiogenic properties, and therefore have the potential to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for severe aplastic anemia (AA).

Aims
To explore the efficacy and safety of allo-HSCT by co-transplantation with MSCs in AA patients

Methods
We conducted a multi-center retrospective study to comparing the incidence and severity of acute GvHD, transplant-related complication and overall survival (OS) of allo-HSCT with or without co-injection of MSCs in AA patients. A total of 75 consecutive severe AA patients (43males/32 females) undergoing allo-HSCT at 4 hospitals from January 2012 to February 2018 were analyzed. 45 patients transplanted with donor HSCs only,and 30 patients transplanted with HSCs and MSCs .MSCs infusion dose was 0.5-3.0×106/kg, at day0/+1 following HSCs infusion.

Results
All patients achieved successful engraftment within one month post transplant. There was no difference in time to leukocyte and platelet engraftment in the two groups. There was a trend to a lower incidence of aGVHD in the MSC group (13.3% versus 26.7%,χ2 =2.066 P=0.151 ). Moreover, a lower incidence of CMV replication in the MSC group was observed (CMV:26.7% vs 64.4 %,P=0.003).With a median follow-up time of 615 days (range:29-2315ays),the 2-yr OS was similar in both groups (76.2% vs 77.3%,P=0.883). A combination of bone marrow and peripheral blood as the sources of stem cells co-transplanted with MSCs (n=9) demonstrated an improved survival benefit (2-yr OS=100%).

Conclusion
These data support that co-transplantation with MSCs could ameliorate the challenges of aGVHD and viremia and facilitate survival in allo-HSCT for AA patients.

Session topic: 22. Stem cell transplantation - Clinical

Keyword(s): Allogeneic hematopoietic stem cell transplant, Anemia

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies